NeoGenomics Names New CEO as Part of Planned Leadership Transition

  • Warren Stone, current President and COO, appointed as CEO effective January 4, 2027.
  • Tony Zook transitions to Executive Chair, maintaining close alignment with Stone.
  • Lynn Tetrault steps down as Board Chair; Michael Kelly becomes Lead Independent Director.
  • Preliminary Q3 2026 revenue estimated at $209M, with 28% YoY NGS revenue growth.

NeoGenomics' leadership transition underscores a deliberate succession plan aimed at maintaining strategic continuity in the competitive oncology diagnostics market. The move comes amid strong financial performance, with Q3 2026 revenue growth highlighting the company's position in precision medicine. The shift in board leadership also signals a focus on long-term governance stability.

Leadership Continuity
How Warren Stone's transition to CEO will impact NeoGenomics' commercial expansion and Lab of the Future initiatives.
Financial Performance
Whether the 28% YoY NGS revenue growth can be sustained and drive full-year revenue guidance increases.
Board Dynamics
The pace at which Michael Kelly, as new Lead Independent Director, will influence strategic decisions.